Unique Patterns of Molecular Profiling Between Human Prostate Cancer LNCaP and PC-3 Cells

Overview

Journal Prostate

Date 2009 Apr 4

PMID 19343732

Citations 48

Authors

Mikhail G Dozmorov

Robert E Hurst

Daniel J Culkin

Bradley P Kropp

Mark Barton Frank

Jeanette Osban

Trevor M Penning

Hsueh-Kung Lin

Affiliations

Soon will be listed here.

Abstract

Background: Human prostate cancer LNCaP and PC-3 cell lines have been extensively used to study prostate cancer progression and to develop therapeutic agents. Although LNCaP and PC-3 cells are generally assumed to represent early and late stages of prostate cancer, respectively, there is limited information regarding gene expression patterns between these two cell lines and its relationship to prostate cancer.

Methods: Comprehensive gene expression analysis was performed. Total RNA was isolated from cultured cells and hybridized to Illumina human BeadChips representing 24,526 transcripts. Bioinformatics analysis was applied to identify cell line specific genes as well as biological mechanisms, pathways, and functions related to the genes.

Results: A total of 2,198 genes were differentially expressed between LNCaP and PC-3 cells. Using a robust statistical analysis and high significance criteria, 115 and 188 genes were identified to be unique to LNCaP and PC-3 cells, respectively. LNCaP cells maintained various metabolic pathways including a gene cluster that encodes UDP-glucuronosyltransferases. Several transcription factors including Tal alpha/beta, GATA-1, and c-Myc/Max may be responsible for regulating LNCaP cell specific genes. By contrast, PC-3 cells were characterized by their unique expression of cytoskeleton-related genes and other genes including VEGFC, IL8, and TGF beta 2.

Conclusions: This study showed that LNCaP and PC-3 cells represent two distinct prostate cancer cell lineages. LNCaP cells retain many prostate cell specific properties, whereas PC-3 cells have acquired a more aggressive phenotype. Future studies for prostate cancer research need to consider similarities and differences between these two cells and their relationship to prostate cancer.

Citing Articles

Chronic hypoxia for the adaptation of extracellular vesicle phenotype.

Pridgeon C, Airavaara K, Monola J, Jokela A, Palmer D, Yliperttula M Sci Rep. 2024; 14(1):25189.

PMID: 39448620 PMC: 11502752. DOI: 10.1038/s41598-024-73453-1.

Nuclear lamin A/C phosphorylation by loss of androgen receptor leads to cancer-associated fibroblast activation.

Ghosh S, Isma J, Ostano P, Mazzeo L, Toniolo A, Das M Nat Commun. 2024; 15(1):7984.

PMID: 39266569 PMC: 11392952. DOI: 10.1038/s41467-024-52344-z.

Multiplex, high-throughput method to study cancer and immune cell mechanotransduction.

Fabiano A, Robbins S, Knoblauch S, Rowland S, Dombroski J, King M Commun Biol. 2024; 7(1):674.

PMID: 38824207 PMC: 11144229. DOI: 10.1038/s42003-024-06327-x.

Extracellular Mechanical Stimuli Alters the Metastatic Progression of Prostate Cancer Cells within 3D Tissue Matrix.

Ditto M, Jacho D, Eisenmann K, Yildirim-Ayan E Bioengineering (Basel). 2023; 10(11).

PMID: 38002395 PMC: 10669840. DOI: 10.3390/bioengineering10111271.

Compartmentalization of androgen receptors at endogenous genes in living cells.

Yavuz S, Kabbech H, van Staalduinen J, Linder S, van Cappellen W, Nigg A Nucleic Acids Res. 2023; 51(20):10992-11009.

PMID: 37791849 PMC: 10639085. DOI: 10.1093/nar/gkad803.

References

Tong A, Fulgham P, Jay C, Chen P, Khalil I, Liu S . MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2008; 16(3):206-16. DOI: 10.1038/cgt.2008.77. View

Levesque E, Turgeon D, Carrier J, Montminy V, Beaulieu M, Belanger A . Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001; 40(13):3869-81. DOI: 10.1021/bi002607y. View

Klossner D, Baust J, VanBuskirk R, Gage A, Baust J . Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. BJU Int. 2008; 101(10):1310-6. DOI: 10.1111/j.1464-410X.2008.07499.x. View

Pozas A, Roos B . A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol. 2000; 167(1-2):43-53. DOI: 10.1016/s0303-7207(00)00300-2. View

Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M . Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids. 2008; 73(9-10):1030-7. DOI: 10.1016/j.steroids.2008.01.028. View

Jin R, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L . The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008; 68(16):6762-9. PMC: 2840631. DOI: 10.1158/0008-5472.CAN-08-0107. View

Song K, Wang H, Krebs T, Kim S, Danielpour D . Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res. 2008; 68(19):8173-82. PMC: 2596934. DOI: 10.1158/0008-5472.CAN-08-2290. View

Robinson D, Zylstra C, Williams B . Wnt signaling and prostate cancer. Curr Drug Targets. 2008; 9(7):571-80. DOI: 10.2174/138945008784911831. View

Tesan T, Gustavsson H, Welen K, Damber J . Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. BJU Int. 2008; 102(8):1034-9. DOI: 10.1111/j.1464-410X.2008.07768.x. View

10.

Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley E, Siegert G . Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008; 10(3):279-86. PMC: 2259456. DOI: 10.1593/neo.07965. View

11.

Gery S, Sawyers C, Agus D, Said J, Koeffler H . TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene. 2002; 21(31):4739-46. DOI: 10.1038/sj.onc.1205142. View

12.

Nakamoto T, Chang C, Li A, Chodak G . Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 1992; 52(3):571-7. View

13.

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

14.

Watt F, Martorana A, Brookes D, Ho T, Kingsley E, OKeefe D . A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics. 2001; 73(3):243-54. DOI: 10.1006/geno.2000.6446. View

15.

Hua J, Balagurunathan Y, Chen Y, Lowey J, Bittner M, Xiong Z . Normalization benefits microarray-based classification. EURASIP J Bioinform Syst Biol. 2008; :43056. PMC: 3171318. DOI: 10.1155/BSB/2006/43056. View

16.

Culig Z, Bartsch G . Androgen axis in prostate cancer. J Cell Biochem. 2006; 99(2):373-81. DOI: 10.1002/jcb.20898. View

17.

Araki S, Omori Y, Lyn D, Singh R, Meinbach D, Sandman Y . Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007; 67(14):6854-62. DOI: 10.1158/0008-5472.CAN-07-1162. View

18.

Barbier O, Belanger A . Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):259-70. DOI: 10.1016/j.beem.2008.01.001. View

19.

Zhong W, Peng J, He H, Wu D, Han Z, Bi X . Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 2008; 31(1):E8-E15. DOI: 10.25011/cim.v31i1.3136. View

20.

Fang J, Ding M, Yang L, Liu L, Jiang B . PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19(12):2487-97. PMC: 2094004. DOI: 10.1016/j.cellsig.2007.07.025. View